Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C

Clin Mol Hepatol. 2016 Mar;22(1):168-71. doi: 10.3350/cmh.2016.22.1.168. Epub 2016 Mar 28.

Abstract

Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment for chronic HCV infection in Korea, which has considerable adverse effects. Acute pancreatitis is a rare complication of PEG-IFN-α administration. We report a case of a 62-year-old female who experienced acute pancreatitis after 4 weeks of PEG-IFN-α-2a and RBV combination therapy for chronic HCV infection. The main cause of the acute pancreatitis in this case was probably PEG-IFN-α rather than RBV for several reasons. A few cases have been reported in which acute pancreatitis occurred during treatment with PEG-IFN-α-2b. This is the first report of acute pancreatitis associated with PEG-IFN-α-2a in Korea.

Keywords: Hepatitis C virus; Pancreatitis; Pegylated interferon alpha-2a.

Publication types

  • Case Reports

MeSH terms

  • Amylases / analysis
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / diagnostic imaging
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use*
  • Lipase / analysis
  • Middle Aged
  • Pancreatitis / etiology*
  • Polyethylene Glycols / adverse effects
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Republic of Korea
  • Ribavirin / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Lipase
  • Amylases
  • peginterferon alfa-2a